tradingkey.logo

electroCore, Inc.

ECOR
查看详细走势图
4.600USD
+0.180+4.07%
收盘 12/19, 16:00美东报价延迟15分钟
35.12M总市值
亏损市盈率 TTM

electroCore, Inc.

4.600
+0.180+4.07%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+4.07%

5天

-3.16%

1月

+0.22%

6月

-10.33%

今年开始到现在

-71.62%

1年

-69.88%

查看详细走势图

TradingKey electroCore, Inc.股票评分

单位: USD 更新时间: 2025-12-19

操作建议

electroCore, Inc.当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名107/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价21.08。中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

electroCore, Inc.评分

相关信息

行业排名
107 / 208
全市场排名
245 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 5 位分析师
买入
评级
21.080
目标均价
+330.20%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

electroCore, Inc.亮点

亮点风险
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
业绩高增长
公司营业收入稳步增长,连续3年增长193.09%
业绩增长期
公司处于发展阶段,最新年度总收入25.18M美元
估值合理
公司最新PE估值-2.70,处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值233.47K
活跃度增加
近期活跃度增加,过去20天平均换手率0.69

electroCore, Inc.新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

electroCore, Inc.简介

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
公司代码ECOR
公司electroCore, Inc.
CEOGoldberger (Daniel S)
网址https://www.electrocore.com/

常见问题

electroCore, Inc.(ECOR)的当前股价是多少?

electroCore, Inc.(ECOR)的当前股价是 4.600。

electroCore, Inc.的股票代码是什么?

electroCore, Inc.的股票代码是ECOR。

electroCore, Inc.股票的52周最高点是多少?

electroCore, Inc.股票的52周最高点是19.490。

electroCore, Inc.股票的52周最低点是多少?

electroCore, Inc.股票的52周最低点是4.160。

electroCore, Inc.的市值是多少?

electroCore, Inc.的市值是35.12M。

electroCore, Inc.的净利润是多少?

electroCore, Inc.的净利润为-11.89M。

现在electroCore, Inc.(ECOR)的股票是买入、持有还是卖出?

根据分析师评级,electroCore, Inc.(ECOR)的总体评级为买入,目标价格为21.080。

electroCore, Inc.(ECOR)股票的每股收益(EPS TTM)是多少

electroCore, Inc.(ECOR)股票的每股收益(EPS TTM)是-1.704。
KeyAI